BOTHELL, Wash.–BLUE HERON BIOTECHNOLOGY announced today that it delivered a critical synthetic DNA gene sequence in just three days in response to the National Institutes of Health request for assistance in combating the outbreak of Swine Flu. “We are gratified that the NIH has placed their confidence and trust in Blue Heron in this time of crisis. We were able to draw on our ten years of gene synthesis expertise to come up with an approach to deliver this critical research tool to the NIH in far less time than usual” said John Mulligan, Blue Heron’s Chief Scientific Officer. The synthesized gene was part of the H1N1 virus and was delivered using Blue Heron’s proprietary GeneMaker gene synthesis platform.

About Blue Heron Biotechnology

Blue Heron Biotechnology, Inc., continues as a pioneer and leader in the gene synthesis market. Since its inception in 1999, Blue Heron Bio has synthesized tens of millions of base pairs of DNA for thousands of life science research organizations including the top pharmaceutical and life science companies. Whether a project requires one gene or thousands of genes, sequences of less than 100 base pairs or over 40,000 base pairs, Blue Heron Bio has the technology and the capacity to meet its customer’s needs. Blue Heron Bio’s proprietary GeneMaker® technology provides access to complex DNA sequences that are difficult or impossible to synthesize with other methods. Customers choose Blue Heron Bio for reliability, customer service, the strength of its technology and its record of success. For more information, visit www.blueheronbio.com.